These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15599982)

  • 1. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 2. The vexations of Vioxx.
    Sibbald B
    CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
    [No Abstract]   [Full Text] [Related]  

  • 3. NEJM editor gives pretrial evidence in Vioxx case.
    Tanne JH
    BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
    [No Abstract]   [Full Text] [Related]  

  • 4. The sad story of Vioxx, and what we should learn from it.
    Karha J; Topol EJ
    Cleve Clin J Med; 2004 Dec; 71(12):933-4, 936, 938-9. PubMed ID: 15641522
    [No Abstract]   [Full Text] [Related]  

  • 5. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 6. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 7. Merck cleared in personal injury case against Vioxx.
    Mayor S
    BMJ; 2005 Nov; 331(7525):1101. PubMed ID: 16282390
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 9. Painful withdrawal for makers of Vioxx: pulling of arthritis drug raises questions on marketing, safety risks.
    Masters BA; Kaufman M
    Washington Post; 2004 Oct; ():A1, A8. PubMed ID: 15586941
    [No Abstract]   [Full Text] [Related]  

  • 10. The Vioxx debacle.
    Fielder JH
    IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852
    [No Abstract]   [Full Text] [Related]  

  • 11. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 12. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 13. How to avoid future Vioxx-type scandals.
    Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US judge dismisses 50m dollars damages in Vioxx lawsuit.
    Charatan F
    BMJ; 2006 Sep; 333(7567):516. PubMed ID: 16960199
    [No Abstract]   [Full Text] [Related]  

  • 15. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
    Fendrick AM
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
    [No Abstract]   [Full Text] [Related]  

  • 16. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 17. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 18. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 19. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 20. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.